Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Onconetix Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

OnconetixDie Gewinne des Unternehmens werden voraussichtlich um 17% pro Jahr sinken, während die jährlichen Einnahmen um 84.4% pro Jahr steigen werden. Der Gewinn pro Aktie wird voraussichtlich decline um 7.8% pro Jahr steigen.

Wichtige Informationen

-17.0%

Wachstumsrate der Gewinne

-7.8%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	30.2%
Wachstumsrate der Einnahmen	84.4%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	08 Nov 2023

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Gewinn- und Umsatzwachstumsprognosen

MUN:J4T - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-26	N/A	N/A	1
12/31/2025	N/A	-20	N/A	N/A	1
12/31/2024	N/A	-16	N/A	N/A	1
12/31/2023	N/A	-13	N/A	N/A	1
9/30/2023	N/A	-18	-22	-12	N/A
6/30/2023	N/A	-17	-20	-11	N/A
3/31/2023	N/A	-14	-12	-12	N/A
12/31/2022	N/A	-14	-9	-9	N/A
9/30/2022	N/A	-12	-7	-7	N/A
6/30/2022	N/A	-9	-5	-5	N/A
3/31/2022	N/A	-6	-3	-3	N/A
12/31/2021	N/A	-4	-2	-2	N/A
9/30/2021	N/A	-3	-2	-2	N/A
6/30/2021	N/A	-2	-1	-1	N/A
3/31/2021	N/A	-2	-1	-1	N/A
12/31/2020	N/A	-2	-2	-2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: J4T wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: J4T wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: J4T wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: J4T wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: J4T wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von J4T in 3 Jahren voraussichtlich hoch sein wird

Onconetix Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Onconetix, Inc. announced delayed 10-Q filing

Onconetix Receives Deficiency Notice from the Nasdaq Regarding Listing Rule 5550(b)(1)

Onconetix, Inc. announced delayed annual 10-K filing

Onconetix, Inc. Announces Appointment of Ajit Singh to its Board of Directors

Onconetix, Inc. Announces Chief Executive Officer Changes

Onconetix, Inc. Announces Resignation of Erin Henderson as Chief Business Officer

Onconetix, Inc. Announces Executive Appointments

Onconetix, Inc.(NasdaqCM:ONCO) dropped from NASDAQ Composite Index

Blue Water Biotech, Inc. (NasdaqCM:BWV) acquired ProteoMediX AG.

Blue Water Biotech, Inc. (NasdaqCM:BWV) acquired ProteoMediX AG.

Blue Water Biotech, Inc. announced delayed 10-Q filing

High number of new and inexperienced directors

Blue Water Biotech, Inc. Appoints Dr. Neil J. Campbell as CEO

Blue Water Biotech Receives Non-Compliance Notice from Nasdaq

Blue Water Biotech, Inc. Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

Blue Water Biotech, Inc. Announces Executive Changes

Blue Water Biotech, Inc. announced delayed 10-Q filing

Blue Water Biotech Secures License from Ohio State Board of Pharmacy to Operate as Pharmaceutical Wholesaler for Its FDA Approved Products

Blue Water Biotech, Inc. Announces Preliminary Preclinical Data Supporting the Use of Its Norovirus Shell and Plusion Virus-Like Particle Platform to Develop Novel Monkeypox Vaccine Candidate

Blue Water Biotech, Inc. (NasdaqCM:BWV) agreed to acquire Six FDA Approved Drugs from WraSer LLC and Xspire Pharma, LLC.

Blue Water Vaccines, Inc. Appoints Frank Jaeger as Senior Vice President of Marketing and Business Development

Blue Water Vaccines Appoints Timothy Ramdeen to Its Board of Directors

Blue Water Vaccines, Inc. (NasdaqCM:BWV) announces an Equity Buyback for $5 million worth of its shares.

Blue Water Vaccines Announces Appointment of Vuk Jeremic, to Its Board of Directors

Blue Water Vaccines Announces Plans to Evaluate Efficacy of Streptococcus Pneumoniae Vaccine Candidate Against Pneumococcal Pneumonia At the World Vaccine Congress in Barcelona

CEO, President & Executive Chairman recently sold €2.7m worth of stock

Blue Water Vaccines, Inc. Announces Appointment of Simon Tarsh to Board of Directors

Blue Water Vaccines, Inc. Announces Exploration of Its Virus-Like Particle (VLP) Platform for Use in Monkeypox Vaccine Candidate

High number of new and inexperienced directors

Blue Water Vaccines, Inc. announced that it has received $9.999998 million in funding

Blue Water Vaccines, Inc. announced that it expects to receive $9.999998 million in funding

Blue Water Vaccines, Inc., Annual General Meeting, Aug 22, 2022

High number of new and inexperienced directors

Blue Water Vaccines, Inc. Presents New Data Supporting Universal Influenza Vaccine Candidate at the World Vaccine Congress 2022 in Washington, DC

Blue Water Vaccines, Inc. announced that it has received $7.999411 million in funding

Blue Water Vaccines, Inc. announced that it expects to receive $8.000001 million in funding

High number of new and inexperienced directors

High number of new and inexperienced directors

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken